Literature DB >> 26865537

Patterns of regional and distant metastasis in esthesioneuroblastoma.

Victoria E Banuchi1,2, Laura Dooley1, Nancy Y Lee3, David G Pfister4, Sean McBride3, Nadeem Riaz3, Mark H Bilsky4, Ian Ganly1, Jatin P Shah1, Dennis H Kraus2, Luc G T Morris1.   

Abstract

OBJECTIVES/HYPOTHESIS: To define the incidence and risk factors of metastatic disease and the effectiveness of salvage therapy in esthesioneuroblastoma (ENB). STUDY
DESIGN: Retrospective analysis of 57 patients presenting from 1979 through 2009.
METHODS: Cumulative incidence of neck failure, distant failure, and survival were assessed using the Kaplan-Meier method.
RESULTS: Overall survival for all patients was 85% at 5 years and 75% at 10 years. Overall survival was negatively impacted by intracranial tumor extension (P < 0.001), positive resection margins (P = 0.05), and neck metastases (P = 0.017). Neck lymph nodes were not routinely electively irradiated during this time period. Nodal metastases developed in 17% of patients at a median time of 60 months. Kadish stage was not associated with a risk of nodal metastasis (P = 0.78). After treatment for nodal recurrence, locoregional control was achieved in 78% of patients. Of patients developing nodal recurrence, more than half developed distant metastases. The cumulative incidence of distant metastasis was 39% at a median time of 40 months. Patients who presented with Kadish stage C or D had a significantly increased risk of distant failure (P < 0.001). In patients developing nodal (P = 0.017) or distant metastasis (P = 0.001), the probability of survival was significantly decreased.
CONCLUSION: Regional and distant metastases in patients with esthesioneuroblastoma occur in a delayed fashion and negatively impact survival. Neck nodal recurrence may be a harbinger of distant metastases. At the Memorial Sloan Kettering Cancer Center, New York, New York, we now treat the majority of ENB patients with elective nodal irradiation. However, the chief obstacle to long-term cure is distant metastases. LEVEL OF EVIDENCE: 4. Laryngoscope, 126:1556-1561, 2016.
© 2016 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Esthesioneuroblastoma; metastasis; neck dissection; olfactory neuroblastoma

Mesh:

Year:  2016        PMID: 26865537      PMCID: PMC4914404          DOI: 10.1002/lary.25862

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  23 in total

1.  Salvage Treatment of Local Recurrence in Esthesioneuroblastoma: A Meta-analysis.

Authors:  Mitchell R Gore; Adam M Zanation
Journal:  Skull Base       Date:  2011-01

2.  Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors.

Authors:  Daniel Jethanamest; Luc G Morris; Andrew G Sikora; David I Kutler
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-03

3.  Olfactory neuroblastoma: a 35-year experience and suggested follow-up protocol.

Authors:  Joanne Rimmer; Valerie J Lund; Timothy Beale; William I Wei; David Howard
Journal:  Laryngoscope       Date:  2014-02-04       Impact factor: 3.325

Review 4.  Esthesioneuroblastoma: a meta-analysis and review.

Authors:  P Dulguerov; A S Allal; T C Calcaterra
Journal:  Lancet Oncol       Date:  2001-11       Impact factor: 41.316

5.  Esthesioneuroblastoma: is there a need for elective neck treatment?

Authors:  Candan Demiroz; Orit Gutfeld; Mohamed Aboziada; Doris Brown; Lawrence J Marentette; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-15       Impact factor: 7.038

6.  Patterns of regional spread for esthesioneuroblastoma.

Authors:  M C Howell; B F Branstetter; C H Snyderman
Journal:  AJNR Am J Neuroradiol       Date:  2011-02-24       Impact factor: 3.825

7.  Esthesioneuroblastoma: reflections of a 21-year experience.

Authors:  P A Levine; R Gallagher; R W Cantrell
Journal:  Laryngoscope       Date:  1999-10       Impact factor: 3.325

8.  Esthesioneuroblastoma: the Johns Hopkins experience.

Authors:  V A Resto; D W Eisele; A Forastiere; M Zahurak; D J Lee; W H Westra
Journal:  Head Neck       Date:  2000-09       Impact factor: 3.147

9.  Olfactory neuroblastoma: past, present, and future?

Authors:  Valerie J Lund; David Howard; William Wei; Margaret Spittle
Journal:  Laryngoscope       Date:  2003-03       Impact factor: 3.325

10.  Esthesioneuroblastoma: an update on the massachusetts eye and ear infirmary and massachusetts general hospital experience with craniofacial resection, proton beam radiation, and chemotherapy.

Authors:  Marc W Herr; Rosh K V Sethi; Joshua C Meier; Kyle J Chambers; Aaron Remenschneider; Annie Chan; William T Curry; Fred G Barker; Daniel G Deschler; Derrick T Lin
Journal:  J Neurol Surg B Skull Base       Date:  2013-09-20
View more
  10 in total

1.  Dural Invasion Predicts the Laterality and Development of Neck Metastases in Esthesioneuroblastoma.

Authors:  John P Marinelli; Jeffrey R Janus; Jamie J Van Gompel; Michael J Link; Eric J Moore; Kathryn M Van Abel; Brandon W Peck; Christine M Lohse; Daniel L Price
Journal:  J Neurol Surg B Skull Base       Date:  2018-02-22

2.  Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma.

Authors:  Rohan R Joshi; Qasim Husain; Benjamin R Roman; Jennifer Cracchiolo; Yao Yu; Jillian Tsai; Julie Kang; Sean McBride; Nancy Y Lee; Luc Morris; Ian Ganly; Viviane Tabar; Marc A Cohen
Journal:  J Surg Oncol       Date:  2018-11-22       Impact factor: 3.454

3.  [68Ga]-DOTATATE PET/CT and PET/MRI in the diagnosis and management of esthesioneuroblastoma: illustrative cases.

Authors:  Michelle Roytman; Andrew B Tassler; Ashutosh Kacker; Theodore H Schwartz; Georgiana A Dobri; Sara B Strauss; Alyssa M Capalbo; Rajiv S Magge; Marissa Barbaro; Eaton Lin; Joseph R Osborne
Journal:  J Neurosurg Case Lessons       Date:  2021-01-11

4.  Olfactory Neuroblastomas: What Actually Happens in the Long-Term?

Authors:  Konstantinos Mantsopoulos; Michael Koch; Heinrich Iro; Jannis Constantinidis
Journal:  J Clin Med       Date:  2022-04-20       Impact factor: 4.964

5.  Changing Trends in the Management of Esthesioneuroblastoma: Irish and International Perspectives.

Authors:  Robbie S R Woods; Thavakumar Subramaniam; Mary Leader; Rory McConn-Walsh; James Paul O'Neill; Peter D Lacy
Journal:  J Neurol Surg B Skull Base       Date:  2017-11-01

Review 6.  Radiation therapy strategies for skull-base malignancies.

Authors:  J D Palmer; M E Gamez; K Ranta; H Ruiz-Garcia; J L Peterson; D M Blakaj; D Prevedello; R Carrau; A Mahajan; K L Chaichana; D M Trifiletti
Journal:  J Neurooncol       Date:  2020-08-12       Impact factor: 4.130

7.  Patterns of failures after surgical resection in olfactory neuroblastoma.

Authors:  Nalee Kim; Chang Geol Lee; Eui Hyun Kim; Chang-Hoon Kim; Ki Chang Keum; Kyu-Sung Lee; Jong Hee Chang; Chang-Ok Suh
Journal:  J Neurooncol       Date:  2018-11-30       Impact factor: 4.130

8.  Non-contiguous Meningeal Recurrence of Olfactory Neuroblastoma: A Case Report and Literature Review.

Authors:  Atsushi Saito; Takashi Sasaki; Tomoo Inoue; Ayumi Narisawa; Takashi Inoue; Shinsuke Suzuki; Masayuki Ezura; Hiroshi Uenohara
Journal:  NMC Case Rep J       Date:  2018-06-28

9.  Genomic analysis identifies frequent deletions of Dystrophin in olfactory neuroblastoma.

Authors:  Gary L Gallia; Ming Zhang; Yi Ning; Michael C Haffner; Denise Batista; Zev A Binder; Justin A Bishop; Christine L Hann; Ralph H Hruban; Masaru Ishii; Alison P Klein; Douglas D Reh; Lisa M Rooper; Vafi Salmasi; Rafael J Tamargo; Qing Wang; Tara Williamson; Tianna Zhao; Ying Zou; Alan K Meeker; Nishant Agrawal; Bert Vogelstein; Kenneth W Kinzler; Nickolas Papadopoulos; Chetan Bettegowda
Journal:  Nat Commun       Date:  2018-12-21       Impact factor: 14.919

10.  Model to predict cause-specific mortality in patients with olfactory neuroblastoma: a competing risk analysis.

Authors:  Lipin Liu; Qiuzi Zhong; Ting Zhao; Dazhi Chen; Yonggang Xu; Gaofeng Li
Journal:  Radiat Oncol       Date:  2021-06-10       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.